Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

NCT06256055 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Mesothelioma
Colorectal Cancer
Bile Duct Cancer
Rectal Cancer
Ovary Cancer
Pancreatic Cancer
Breast Cancer Female

Interventions

BIOLOGICAL: UCMYM802 Injection

Sponsor

UTC Therapeutics Inc.

Collaborators

[object Object]